Two Sigma Advisers’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-59,400
| Closed | -$4.94M | – | 2396 |
|
|
2025
Q3 | $4.94M | Sell |
59,400
-70,700
| -54% | -$5.12M | 0.01% | 753 |
|
|
2025
Q2 | $9.55M | Sell |
130,100
-176,700
| -58% | -$12.8M | 0.02% | 517 |
|
|
2025
Q1 | $35M | Sell |
306,800
-75,000
| -20% | -$4.56M | 0.08% | 228 |
|
|
2024
Q4 | $19.2M | Sell |
381,800
-75,300
| -16% | -$3.95M | 0.04% | 330 |
|
|
2024
Q3 | $21.2M | Sell |
457,100
-57,900
| -11% | -$2.06M | 0.05% | 311 |
|
|
2024
Q2 | $16.7M | Sell |
515,000
-245,200
| -32% | -$6.72M | 0.04% | 389 |
|
|
2024
Q1 | $19.1M | Buy |
760,200
+223,800
| +42% | +$5.29M | 0.04% | 358 |
|
|
2023
Q4 | $17.4M | Buy |
536,400
+126,700
| +31% | +$3.48M | 0.04% | 371 |
|
|
2023
Q3 | $11.2M | Buy |
409,700
+98,100
| +31% | +$2.84M | 0.03% | 440 |
|
|
2023
Q2 | $6.93M | Buy |
+311,600
| New | +$7.17M | 0.02% | 625 |
|
|
2021
Q1 | – | Sell |
-14,700
| Closed | -$385K | – | 2589 |
|
|
2020
Q4 | $385K | Sell |
14,700
-22,700
| -61% | -$478K | ﹤0.01% | 1959 |
|
|
2020
Q3 | $651K | Sell |
37,400
-90,000
| -71% | -$1.43M | ﹤0.01% | 1699 |
|
|
2020
Q2 | $2.14M | Buy |
127,400
+91,000
| +250% | +$1.28M | 0.01% | 1172 |
|
|
2020
Q1 | $433K | Buy |
+36,400
| New | +$450K | ﹤0.01% | 1862 |
|
|
2019
Q4 | – | Sell |
-13,200
| Closed | -$187K | – | 2370 |
|
|
2019
Q3 | $187K | Buy |
13,200
+2,200
| +20% | +$27K | ﹤0.01% | 2054 |
|
|
2019
Q2 | $123K | Sell |
11,000
-20,303
| -65% | -$226K | ﹤0.01% | 2192 |
|
|
2019
Q1 | $367K | Buy |
31,303
+6,000
| +24% | +$74.6K | ﹤0.01% | 1916 |
|
|
2018
Q4 | $338K | Buy |
+25,303
| New | +$334K | ﹤0.01% | 1929 |
|
|
2018
Q2 | – | Sell |
-128,894
| Closed | -$2.12M | – | 2383 |
|
|
2018
Q1 | $2.12M | Sell |
128,894
-95,300
| -43% | -$1.77M | 0.01% | 1220 |
|
|
2017
Q4 | $4.05M | Sell |
224,194
-68,100
| -23% | -$1.23M | 0.01% | 928 |
|
|
2017
Q3 | $5.64M | Buy |
292,294
+129,000
| +79% | +$1.92M | 0.02% | 755 |
|
|
2017
Q2 | $1.93M | Sell |
163,294
-53,000
| -25% | -$576K | 0.01% | 1225 |
|
|
2017
Q1 | $2.37M | Sell |
216,294
-60,006
| -22% | -$527K | 0.01% | 1170 |
|
|
2016
Q4 | $2.01M | Buy |
276,300
+120,213
| +77% | +$942K | 0.01% | 1176 |
|
|
2016
Q3 | $1.01M | Buy |
156,087
+6,000
| +4% | +$34.9K | ﹤0.01% | 1346 |
|
|
2016
Q2 | $819K | Sell |
150,087
-13,900
| -8% | -$72.3K | ﹤0.01% | 1262 |
|
|
2016
Q1 | $767K | Sell |
163,987
-16,191
| -9% | -$63.1K | ﹤0.01% | 1256 |
|
|
2015
Q4 | $897K | Sell |
180,178
-13,420
| -7% | -$60.5K | 0.01% | 1077 |
|
|
2015
Q3 | $766K | Buy |
193,598
+139,611
| +259% | +$708K | ﹤0.01% | 1125 |
|
|
2015
Q2 | $324K | Buy |
+53,987
| New | +$331K | ﹤0.01% | 1588 |
|
Other funds holding CORT
ISL
PA
Two Sigma Advisers's CORT Position: Q4 2025 in Review
Two Sigma Advisers sold out of Corcept Therapeutics (CORT) in Q4 2025, closing a stake of 59,400 shares — an estimated $4.94M sold.
Two Sigma Advisers first reported a position in CORT in Q2 2015 and held it in 30 quarters. The position peaked at $35M in Q1 2025. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.
- Two Sigma Advisers reported no remaining Corcept Therapeutics position as of Q4 2025 after selling out during the quarter.
- Two Sigma Advisers sold 59,400 Corcept Therapeutics shares in Q4 2025, an estimated $4.94M.
- Two Sigma Advisers first reported a position in Corcept Therapeutics in Q2 2015 and held it in 30 quarters.
- Two Sigma Advisers's Corcept Therapeutics position peaked at $35M in Q1 2025.
- 389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.
Based on Two Sigma Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.